The Role of Manipulating Lipids in Uremia

  • Thomas A. Golper


Since the manipulation of lipids is such a broad subject, this chapter will specifically address the issue of hyperlipidemia (HL) associated with maintenance dialysis therapy.


Chronic Renal Failure Hemodialysis Patient Continuous Ambulatory Peritoneal Dialysis Uremic Patient Maintenance Hemodialysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bagdade JD, Albers JJ: Plasma high-density lipoprotein concentrations in chronic-hemo-dialysis and renal-transplant patients. N Engl J Med 296:1436, 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    Frank WM, Rao TKS, Manis T, Delano BG, Avrom MM, Saxene AK, Carter AC, Friedman EA: Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis. Am J Clin Nutr 31:1886, 1978.PubMedGoogle Scholar
  3. 3.
    Gutman RA, Uy A, Shalhoub RJ, Wade AD, O’Connell JMB, Recont L: Hypertriglyceridemia in chronic nonnephrotic renal failure. Am J Clin Nutr 26:165, 1973.PubMedGoogle Scholar
  4. 4.
    Ibels LS, Simons LA, King JO, Williams PF, Neale FC, Stewart JM: Studies on the nature and causes of hyperlipidemia in uraemia, maintenance dialysis, and renal transplantation. QJ Med 44:601, 1975.Google Scholar
  5. 5.
    Ponticelli C, Barbi G, Cantaluppi A, Donati C, Annoni G, Brancaccio D: Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int 13 (suppl 8):S–72, 1978.Google Scholar
  6. 6.
    Brown DF, Kinch SH, Doyle JT: Serum triglyceride in health and in ischemic heart disease. N Engl J Med 273:947, 1965.PubMedCrossRefGoogle Scholar
  7. 7.
    Carlson LA, Bottiger LE: Ischaemic heart diseases in relation to fasting values of plasma triglycerides and cholesterol. Lancet 1:865, 1972.PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenmann RH, Brand RJ, Jenkins CD, Friedman M, Straus R, Wurm M: Coronary heart disease in the Western Collaborative Group Study. JAMA 233:872, 1975.CrossRefGoogle Scholar
  9. 9.
    Haas LB, Sherrard DJ, Brunzell JD: Hypertriglyceridemia and premature cardiovascular disease in patients on maintenance hemodialysis. Clin Res 27:416A, 1979.Google Scholar
  10. 10.
    Henriquez M, Raja R, Kramer M, Rosenbaum JL: Role of high density lipoproteins in cardiovascular disease in hemodialyzed patients. Am Soc Artif Int Organs, 44, 1979 (abstr).Google Scholar
  11. 11.
    Brunzell JD, Albers JJ, Haas LB, Agadoa L, Goldberg AP, Sherrard DJ: Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 26:903, 1977.PubMedCrossRefGoogle Scholar
  12. 12.
    Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease: New perspectives based on the Framingham study. Ann Intern Med 90:85, 1979.PubMedGoogle Scholar
  13. 13.
    Stamler J: The coronary drug project (Clofibrate and niacin in coronary heart disease). JAMA 231:360, 1975.CrossRefGoogle Scholar
  14. 14.
    Committee of Principal Investigators: A cooperative trial in the primary prevention of ischaemic heart disease using Clofibrate. Br Heart J 40:1069, 1978.CrossRefGoogle Scholar
  15. 15.
    Dayton S, Pearce WL, Hashimoto S, Dixon WJ, Tomiyasu U: A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 39, 40 (suppl 2):II–I1, 1969.Google Scholar
  16. 16.
    Miettinen M, Turpeinen O, Karvonen MJ, Elosno R, Paavilainen E: Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes (12 year clinical trial in men and women). Lancet 2:835, 1972.PubMedCrossRefGoogle Scholar
  17. 17.
    Leren P: The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. Acta Med Scand (suppl) 466:5, 1966.Google Scholar
  18. 18.
    Barndt R, Blankenhorn DH, Crawford DW, Brooks SH: Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Intern Med 86:139, 1977.PubMedGoogle Scholar
  19. 19.
    Basta LL, Williams C, Kioschos JM, Spector AA: Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cure of systemic hypertension though control of hyperlipidemia. Am J Med 61:420, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697, 1974.PubMedCrossRefGoogle Scholar
  21. 21.
    Lazarus JM, Lowrie EG, Hampers CL, Merrill JP: Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 7 (suppl 2):S–167, 1975.Google Scholar
  22. 22.
    Levy RI, Morganroth J, Rikfind BM: Treatment of hyperlipidemia. N Engl J Med 290:1295, 1974.PubMedCrossRefGoogle Scholar
  23. 23.
    Swamy AP, Cestero RVM, Campbell RG: Lipid changes in maintenance hemodialysis. Am Soc Nephrol. 54A, 1978 (abstr).Google Scholar
  24. 24.
    Goldberg AP, Hagberg JM, Delmez JA, Heath GW, Hartes HR: Exercise training corrects abnormal lipid and carbohydrate metabolism in hemodialysis patients. Trans Am Soc Artif Morgans 25:431, 1979.CrossRefGoogle Scholar
  25. 25.
    Goldberg AP, Hagberg JM, Delmez JA, Carney RM, McKenitt PM, Ehsani AA, Harter HR: The metabolic and psychological effects of exercise in hemodialysis patients. Am J Clin Nutr 33:1620, 1980.PubMedGoogle Scholar
  26. 26.
    Amend WJC, Steinberg SM, Lowrie EG, Lazarus JM, Soeldner JC, Hampers CL, Merrill JP: The influence of serum calcium and parathyroid hormone upon glucose metabolism in uremia. J Lab Clin Med 86:435, 1975.PubMedGoogle Scholar
  27. 27.
    Hallberg D, Werner S: Circulatory and lipolytic effects of parathyroid hormone. Hormone Metab Res 9:424, 1977.CrossRefGoogle Scholar
  28. 28.
    Sinha TK, Thajchayapong P, Queener SF, Allen DO, Bell NH: On the lipolytic action of parathyroid hormone in man. Metabolism 25:251, 1976.PubMedCrossRefGoogle Scholar
  29. 29.
    Kather H, Heuck CC, Tschope W, Ritz E, Simon B: Unchanged hormone sensitivity of rat fat cell adenylate cyclase in uremia. Clin Nephrol 8:324, 1977.PubMedGoogle Scholar
  30. 30.
    Cantin M: Kidney, parathyroid and lipemia. Lab Invest 14:1691, 1965.PubMedGoogle Scholar
  31. 31.
    Tuma SN, Seidel CL, Entman ML: Relaxing effect of parathyroid extract on the smooth muscle of rabbit aorta. Am Soc Nephrol, p. 90A, 1979.Google Scholar
  32. 32.
    Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66:790, 1979.PubMedCrossRefGoogle Scholar
  33. 33.
    Delavelle F, Trombert JC, Canarelli G: HDL cholesterol as cardiovascular risk factor in uremia. Kidney Int 16:94, 1979.CrossRefGoogle Scholar
  34. 34.
    Daubresse JC, Lerson G, Plamteux G, Rorive G, Luyckx AS, Lefebure PJ: Lipids and lipoproteins in chronic uremia. A study of the influence of regular haemodialysis. Eur J Clin Invest 6:159, 1976.PubMedCrossRefGoogle Scholar
  35. 35.
    Wochos DN, Anderson CF, Mitchell JC: Serum lipids in chronic renal failure. Mayo Clin Proc 51:660, 1976.PubMedGoogle Scholar
  36. 36.
    Heuck CC, Ritz E, Liersch M, Mehls O: Serum lipids in renal insufficiency. Am J Clin Nutr 31:1547, 1978.PubMedGoogle Scholar
  37. 37.
    Sorge F, Castro LA, Nagel A, Kessel M: Serum glucose, insulin, growth hormone, free fatty acids and lipids responses to high carbohydrate and to high fat isocaloric diets in patients with chronic, non-nephrotic renal disease. Hormone Metab Res 7:118, 1975.CrossRefGoogle Scholar
  38. 38.
    Sanfelippo ML, Swenson RS, Reaven GM: Response of plasma triglycerides to dietary changes in patients on hemodialysis. Kidney Int 14:180, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    Gokal R, Mann JI, Oliver O, Ledingham JGG: Dietary treatment of hyperlipidemia in chronic hemodialysis patients. Am J Clin Nutr 31:1915, 1978.PubMedGoogle Scholar
  40. 40.
    Connor WE, Connor SL: Dietary treatment of hyperlipidemia, in Rifkind BM, Levy RI (eds): Hyperlipidemia: Diagnosis and Therapy. New York, Grune & Stratton, 1977.Google Scholar
  41. 41.
    Savdie E, Mahony JF, Steward JH: Effect of acetate on serum lipids in maintenance hemodialysis. Trans Am Soc Artif Int Organs 23:385, 1977.CrossRefGoogle Scholar
  42. 42.
    Kluge R, Heuck C. Wildberger D, Wirth A, Ritz E: Dialysate bicarbonate and hyperlipidemia. Am Soc Artif Int Organs p. 73, 1979 (abstr).Google Scholar
  43. 43.
    Giorcelli G, Dalmasso F, Bruno M, Pellegrino S, Sirkka M, Vacha G: RDT with acetate-free bicarbonate buffered dialysis fluid: Long-term effects on lipid pattern, acid-base balance and oxygen delivery. Kidney Int 16:223, 1979.Google Scholar
  44. 44.
    Port FK, Easterling RE, Barnes RV: Effect of acetate administration on blood lipids. Am J Clin Nutr 31:1893, 1978.PubMedGoogle Scholar
  45. 45.
    Davidson WD, Rorke SJ, Guo LSS, Morin RJ: Comparison of acetate-1-14C metabolism in uremic and nonuremic dogs. Am J Clin Nutr 31:1897, 1978.PubMedGoogle Scholar
  46. 46.
    Perez-Garcia A, Breto M, Alvarino J, Alegre B, Cruz JM: The influence of several factors that intervene in hemodialysis on serum levels of triglycerides and free fatty acids. Clin Nephrol 12:14, 1979.PubMedGoogle Scholar
  47. 47.
    Heuck CC, Ritz E, Kluge R, Wildeberger D, Wirth A: High density lipoprotein composition in chronic hemodialysis. N Engl J Med 300:1055, 1979.PubMedCrossRefGoogle Scholar
  48. 48.
    Graefe U, Milutinovich J, Follette WC, Vizzo JE, Babb AL, Scribner BH: Less dialysis-induced morbidity and vascular instability with bicarbonate in dialysate. Ann Intern Med 88:332, 1978.PubMedGoogle Scholar
  49. 49.
    Hubner W, Sieberth HG, Diemer A, Finke K, Prange E: Effects of regular haemodialysis with glucose and glucose free dialysate on hyperlipidemia. Proc Eur Dial Transpl Assoc 8:174, 1971.Google Scholar
  50. 50.
    Dombeck DH, Lundholm DD, Vieira JA: Lipid metabolism in uremia and the effects of dialysate glucose and oral androgen therapy. Trans Am Soc Artif Int Organs 19:150, 1973.CrossRefGoogle Scholar
  51. 51.
    Novarini A, Zuliani U, Bandini L, Laronna S, Montanari A, Perinotto P: Observations on lipid metabolism in chronic renal failure, during conservative and haemodialysis therapy. Eur J Clin Invest 6:473, 1976.CrossRefGoogle Scholar
  52. 52.
    Swamy AP, Cestero RUM, Campbell RG, Freeman RB: Long-term effect of dialysate glucose on the lipid levels of maintenance hemodialysis patients. Trans Am Soc Artif Int Organs 22:54, 1976.Google Scholar
  53. 53.
    Wathen R, Keshaviah P, Hommeyer P, Cadwell K, Comty G: Role of dialysate glucose in preventing gluconeogenesis during hemodialysis. Trans Am Soc Artif Int Organs 23:393, 1977.CrossRefGoogle Scholar
  54. 54.
    Cattran DC, Fenton SSA, Wilson DR, Steiner G: Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. Ann Intern Med 85:29, 1976.PubMedGoogle Scholar
  55. 55.
    Felts JM, Zacherle B, Staprans I, Itakura H: Mechanisms of hyperlipidemia in chronic renal failure. Contract NO-1-AM-4-2220, 10th Annual Contractor’s Conference, NIAMDD:10, 1977.Google Scholar
  56. 56.
    Ibels LS, Reardon MF, Nestel PJ: Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients. J Lab Clin Med 87:648, 1976.PubMedGoogle Scholar
  57. 57.
    Bagdade JD. Uremic lipemia: An unrecognized abnormality in triglyceride production and removal. Arch Intern Med 126:875, 1970.PubMedCrossRefGoogle Scholar
  58. 58.
    Samar RE, Moncrief JW, Decherd JF, Popovich RP: Lipoprotein binding and hypertriglyceridemia in chronic uremia. Trans Am Soc Artif Int Organs 21:455, 1975.Google Scholar
  59. 59.
    Roncari DAK, Breckenridge WC, Ogilvie R, Katirtzoglan A, Oreopoulos DG: Lipoprotein metabolism in patients treated with continuous ambulatory peritoneal dialysis. Am Soc Nephhol, 184A, 1979 (abstr).Google Scholar
  60. 60.
    Sanfelippo M, Barg A, Henderson L: Altered lipid and insulin response in hemodialysis patients after hemofiltration. Am Soc Nephrol, 128A, 1979 (abstr).Google Scholar
  61. 61.
    Sanfelippo M, Grundy S, Henderson L: Transport of very low density lipoprotein triglyceride: Comparison of hemodialysis and hemofiltration. Am Soc Nephrol, p 96A, 1979 (abstr).Google Scholar
  62. 62.
    Rosenthal T, Holtzman E, Segal P: The effect of chlorthalidone on serum lipids and lipoproteins. Atherosclerosis 36:111, 1980.PubMedCrossRefGoogle Scholar
  63. 63.
    Friedman EI, Feinstein EI, Beyer MM, Galonsky RS, Hirsch SR: Charcoal-induced lipid reduction in uremia. Kidney Int 13 (suppl 8):S–170, 1978.Google Scholar
  64. 64.
    Gokal R, Mann JI, Oliver DO, Ledingham JGG: Treatment of hyperlipidemia in patients on chronic haemodialysis. Br Med J 1:82, 1978.PubMedCrossRefGoogle Scholar
  65. 65.
    Goldberg AP, Sherrard DJ, Haas LB, Brunzell JD: Control of Clofibrate toxicity in uremic hypertriglyceridemia. Clin Pharmacol Ther 21:317, 1977.PubMedGoogle Scholar
  66. 66.
    Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Einholm CJ, Nikkila EA: Increase in lipoprotein lipase during Clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301:1073, 1979.PubMedCrossRefGoogle Scholar
  67. 67.
    di Giulio S, Boulu R, Drueke T, Nicolai A, Zingraff J, Crosnier J: Clifobrate treatment of hyperlipidemia in chronic renal failure. Clin Nephrol 8:504, 1977.PubMedGoogle Scholar
  68. 68.
    Comty CM, Hemphill G, Wathen RL: Use of Clofibrate in treatment of hyperlipidemia of chronic hemodialysis patients. Am Soc Artif Int Organs, p 15, 1977 (abstr).Google Scholar

Copyright information

© Plenum Publishing Corporation 1985

Authors and Affiliations

  • Thomas A. Golper
    • 1
  1. 1.University of Oregon Health Sciences CenterPortlandUSA

Personalised recommendations